We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PAREXEL Launches Expanded Genomic Research Services
Product News

PAREXEL Launches Expanded Genomic Research Services

PAREXEL Launches Expanded Genomic Research Services
Product News

PAREXEL Launches Expanded Genomic Research Services


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PAREXEL Launches Expanded Genomic Research Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PAREXEL International Corporation has announced expanded services and capabilities in genomic-based drug development. The PAREXEL® Genomic Medicine team offers clients a variety of strategic and operational genomic research services to accelerate drug development and to support regulatory and payer approval processes.

Biopharmaceutical companies are increasingly applying genomics to drug discovery and development to better understand the genetic basis of disease, drug targets, and drug response. Over the next five years, the number of personalized medicines in development is expected to increase 69 percent.

Additionally, regulators and payers are increasingly seeking genomic information to inform decision-making and assure a product delivers clinical utility and value for the intended patient population. In 2015, 20 percent of FDA approvals were for targeted therapies. Researchers have also shown that drug mechanisms with genetic evidence may be twice as likely to receive regulatory approval.

“Recently, the terms ‘precision medicine’ and ‘personalized medicine’ have become household terms, and genomic research is the key to developing targeted therapies. By applying innovative and methodologies, we work with our clients to understand how genes impact an individual’s response to treatment – and why people who receive the same treatment may respond differently,” said Sy Pretorius, M.D., Chief Scientific Officer, PAREXEL.

“PAREXEL’s Genomic Medicine team leverages genomic information across more than 10 therapeutic areas to help biopharmaceutical companies discover, develop, and secure regulatory and payer approval for their new medicines.”

PAREXEL’s Genomic Medicine team is comprised of more than 15 scientists with an aggregate of nearly 300 years of combined experience in genomics, drug discovery, and drug development. The team joined PAREXEL from GlaxoSmithKline’s Genetics and Computational Biology departments.

Advertisement